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Abstract
Rationale: Idiopathicpulmonaryﬁbrosis (IPF) isaprogressive lungdisease
of unknown cause that leads to respiratory failure and death within 5 years
of diagnosis. Overt respiratory infection and immunosuppression carry
a high morbidity andmortality, and polymorphisms in genes related to
epithelial integrity and host defense predispose to IPF.
Objectives: To investigate the role of bacteria in the pathogenesis
and progression of IPF.
Methods:We prospectively enrolled patients diagnosed with IPF
according to international criteria together with healthy smokers,
nonsmokers, andsubjectswithmoderatechronicobstructivepulmonary
disease as control subjects. Subjects underwent bronchoalveolar
lavage (BAL), from which genomic DNA was isolated. The V3–V5
region of the bacterial 16S rRNA gene was ampliﬁed, allowing
quantiﬁcation of bacterial load and identiﬁcation of communities by 16S
rRNA quantitative polymerase chain reaction and pyrosequencing.
Measurements and Main Results: Sixty-ﬁve patients with IPF
had double the burden of bacteria in BAL ﬂuid comparedwith 44 control
subjects. Baseline bacterial burden predicted the rate of decline in lung
volume and risk of death and associated independently with the
rs35705950 polymorphism of the MUC5Bmucin gene, a proven host
susceptibility factor for IPF. Sequencingyielded912,883high-quality reads
fromall subjects.We identiﬁedHaemophilus,Streptococcus,Neisseria, and
Veillonella spp. to be more abundant in cases than control subjects.
Regression analyses indicated that these speciﬁc operational taxonomic
units as well as bacterial burden associated independently with IPF.
Conclusions: IPF is characterized by an increased bacterial burden
in BAL that predicts decline in lung function and death. Trials of
antimicrobial therapy are needed to determine if microbial burden
is pathogenic in the disease.
Keywords: idiopathic pulmonary ﬁbrosis; Muc5b; bacteria;
microbiome
Idiopathic pulmonary ﬁbrosis (IPF) is
a progressive and fatal disease of unknown
cause (1). It is increasing in prevalence (2),
has a median survival from diagnosis of
3 years, and carries a worse life expectancy
than some cancers (3). IPF occurs primarily
in older adults, many of whom have been
smokers, and polymorphisms in genes
related to epithelial integrity and host
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defense predispose to the disease (4–8).
Epidemiological studies suggest that
environmental factors may be integral to
the pathogenesis of IPF in genetically
susceptible individuals (9).
The minor allele of a polymorphism
(rs35705950) in the promoter of the mucin
gene MUC5B is a known host factor that
confers an increased risk of developing
IPF (4, 6, 10). In mice, Muc5b appears
essential for normal macrophage function
and effective mucociliary clearance of
bacteria (11), supporting a potential role
for infection as an environmental trigger in
susceptible individuals (12). Although
viruses may play a part in the initiation
and progression of disease and may also
be responsible for a proportion of acute
exacerbations (13), the role of bacteria in
the pathogenesis and progression of IPF
has not yet been studied in detail (14).
Active infection in IPF is, however,
known to carry a high morbidity and
mortality (15). In individuals with IPF,
immunosuppression is clearly deleterious
(16). Treatment-adherent subjects in
a large trial of the use of prophylactic
cotrimoxazole in IPF experienced
a reduction in overt infections and
mortality (17).
We therefore investigated the role of
bacteria in the pathogenesis and progression
of IPF in a substantial prospective case-
control study. As IPF often appears against
a background of smoking-related lung
disease, we included patients with chronic
obstructive pulmonary disease (COPD)
and matched numbers of smokers in our
control groups. We used sequence-based
culture-independent methodologies to
quantify both the numbers of bacterial
genomes and the community composition
of specimens collected by bronchoalveolar
lavage. Some of the results of these studies
have been previously reported in the form
of an abstract (18).
Methods
Study Design
Patients undergoing diagnostic bronchoscopy
with bronchoalveolar lavage (BAL) for
suspected but previously undiagnosed
IPF were prospectively recruited between
November 2010 and January 2013. A
diagnosis of IPF was made after
multidisciplinary team discussion. Only
individuals fulﬁlling currently accepted
international criteria were subsequently
included in the study (19). Control subjects
included nonsmokers and smokers
with normal lung function (referred to
throughout as healthy control subjects)
and individuals with moderate (Global
Initiative for Chronic Obstructive Lung
Disease stage II) COPD and were recruited
separately using the same protocols.
Subjects were excluded if they had
a history of self-reported upper or lower
respiratory tract infection, antibiotic use
in the prior 3 months, acute IPF
exacerbation, or other respiratory
disorders. Written informed consent was
obtained from all subjects, and the study
was approved by the local Research Ethics
Committee (Ref 10/H0720/12, 00/BA/
459E, and 07/H0712/138).
Bronchoscopy
Fiberoptic bronchoscopy with BAL was
performed via the oropharyngeal route in
accordance with American Thoracic Society
guidelines (20). Aliquots of saline, to
a total volume of 240 ml, were separately
instilled in to a segment of the right
middle lobe. The bronchoscopies were
all performed according to a standard
operating procedure. Post collection, an
aliquot of unﬁltered and unprocessed BAL
was immediately placed on ice then
frozen at 2808C by the bronchoscopist.
Negative control samples were collected
by aspirating buffered saline through the
bronchoscope suction channel before
bronchoscopy. BAL ﬂuid was examined for
the presence of macrophages to conﬁrm
access of the alveolar compartment,
and the absence of ciliated epithelium
was used to exclude large airway
contamination.
DNA Extraction
Two 2-ml aliquots of BAL were centrifuged
at 20,000 3 g for 15 minutes, to pellet
cell debris and bacteria, and genomic
DNA was then isolated using the MP
Bio FastDNA SPIN Kit for Soil (http://
www.mpbio.com) as previously described
(21).
Genotyping
Genotypes of the MUC5B SNP rs35705950
were determined using TaqMan assays
(Life Technologies, Carlsbad, CA).
Reactions were performed in 384-well
plates, and ﬂuorescence was read using
an Applied Biosystems Viia7 Sequence
Detection System.
16S rRNA Gene Quantitative
Polymerase Chain Reaction and
Pyrosequencing
The V3–V5 region of the bacterial 16S
rRNA gene was ampliﬁed using the 357F
forward primer and the 926R reverse
primer for both 16S quantitative
polymerase chain reaction (qPCR) and
pyrosequencing as previously described
(21). The barcoded pyrosequence reads
were processed using QIIME 1.7.0 (22).
Initial denoising was performed to
remove sequencing errors (23), and PCR-
generated artifacts were removed using
ChimeraSlayer (24). Sequences were
clustered into operational taxonomic
units (OTUs) at 97% identity (25),
aligned to full-length 16S rRNA
sequences (26), and assigned a taxonomic
identity with the Ribosomal Database
Project classiﬁer using the SILVA
reference database.
Statistical Analysis
Continuous variables are presented as
means (6SD) and categorical variables
as proportions. Metastats was used to
perform nonparametric t test comparisons
At a Glance Commentary
Scientiﬁc Knowledge on the
Subject: Idiopathic pulmonary
ﬁbrosis (IPF) is a progressive and
fatal disease of unknown cause. Active
infection in IPF is known to be
associated with high morbidity and
mortality, and immunosuppression is
deleterious. Although the role of
viruses in the pathogenesis and
progression of IPF has been
investigated, the role of bacteria
has not been studied in detail.
What This Study Adds to the
Field: Patients with IPF have an
increased pulmonary bacterial load
compared with matched control
subjects, and the load at the time
of diagnosis predicts rapidly
progressive IPF and an increased risk
of mortality. Clinical trials of
antimicrobial therapy are needed to
determine if microbial burden is causal
or not in IPF progression.
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of microbial communities between
groups (27), with P values corrected for
multiple hypotheses testing using the
FDR approach of Benjamini and Hochberg.
We restricted testing to OTUs that had
a differing mean abundance between cases
and control subjects of more than 1% of the
total. Shannon’s entropy (28) (a diversity
index) and weighted and unweighted
UniFrac distances (29) (b diversity)
were calculated in QIIME. The time-to-
event curves were calculated using the
Kaplan–Meier method and compared with
the use of the log-rank test. Differences
between subject groups were evaluated
with the use of the Mann–Whitney test
for continuous variables and Fisher exact
test for categorical variables. Spearman
rho was used to calculate correlations
between continuous variables. The
statistical signiﬁcance of association of
variables with a diagnosis of IPF was
assessed using a stepwise backward
elimination logistic regression process to
select among potential covariates for
inclusion in the ﬁnal model. The statistical
signiﬁcance of association of variables
with genotypes of the MUC5B SNP
rs35705950 (coded 0, 1, and 2) were
modeled using multiple permutations of
the data (bootstrapping). All analyses were
performed with the use of SPSS (version 21)
and R (http://cran.r-project.org/). A two-
sided P value of less than 0.05 was
considered to indicate statistical
signiﬁcance.
Results
Subjects, Sampling, and Sequencing
Seventy-ﬁve patients with suspected IPF
and 44 control subjects (27 healthy control
subjects and 17 subjects with moderate
COPD) (Table 1) were enrolled in the
study and underwent bronchoscopy.
During the study period, nine further
patients with suspected IPF were excluded
from enrollment because they reported
symptoms of a lower respiratory tract
infection or antibiotic usage in the
preceding 3 months. A ﬁnal diagnosis of
IPF was made after multidisciplinary
team discussion; 10 of the 75 recruited
patients did not fulﬁll the American
Thoracic Society diagnostic criteria for
IPF and were subsequently excluded from
the study (19).
The remaining 65 subjects with IPF
were predominantly men (77%), with
a mean age of 68 years, and had moderately
severe disease at enrollment (carbon
monoxide diffusing capacity [DLCO], 44.7%
predicted; FVC, 76.5% predicted). Nine of
the 65 subjects with IPF had coexisting
emphysema based on high-resolution
computed tomography scan, and in all
cases the extent of emphysema was less
than the extent of ﬁbrosis on computed
tomography. The 44 control subjects were
matched for smoking history and sex but
were younger than the IPF cohort, with
a mean age of 58.2 years (Table 1). None
of the control group and only four of
the subjects with IPF were using inhaled
corticosteroids at the time of their
assessment.
Bacterial 16S rRNA sequencing was
performed on extracted genomic DNA
from all 109 subjects, and after denoising,
chimera checking, and singleton removal
a total of 912,883 high-quality reads
remained, with on an average 5,851 reads
per sample. To control for bias of per-
sample read coverage, we randomly
resampled (rareﬁed) sequences to the same
minimum of 796 reads for all subjects.
Sequences were then clustered by sequence
similarity into OTUs, which are
approximately analogous to a bacterial
species, and this ﬁnal dataset was used in
all subsequent analyses. There were 464
OTUs identiﬁed across the IPF and control
panels, and less than 5% of the sequences
were unclassiﬁable by reference to the
SILVA reference database. All processing of
the samples to DNA was performed by
P.L.M. qPCR and sequencing of control
subjects and IPF samples were performed
together in a single batch, to control for
the potential effects of batch and operator
variability. The full data set can be downloaded
from http://lungen.bioinformatics.ic.ac.uk/
data/microbiome_ipf.
Bacterial Burden
First, we explored the differences in BAL
bacterial load (burden) between cases versus
control subjects. We found that on average,
subjects with IPF had 1.9 3 108 copies of
Table 1. Baseline Characteristics of the Patients
Characteristics
IPF
(n = 65)
Combined Control
Subjects (n = 44)
Subjects with
COPD (n = 17)
Healthy Subjects
(n = 27) P Value*
Age, yr 68 (68.2) 58.2 (68.0) 60 (68.5) 58 (617.6) , 0.0001
Female sex, n (%) 15 (23) 17 (28) 5 (29) 12 (44) NS
Smoking (ever vs never), n (%) 43 (65) 28 (63) 17 (100) 11 (40) NS
FVC, % 76.5 (618) 100 (614) 93.0 (613) 104.4 (614) , 0.0001
FEV1, % 77 (615) 88.5 (619) 69.6 (615) 100.4 (612) , 0.005
Ratio of FEV1 to FVC 80.0 (67) 71.3 (611) 59.9 (69) 78.6 (65) , 0.0001
Carbon monoxide diffusion capacity,
% of predicted value
44.7 (613) 78.8 (618) 72.3 (619) 84.0 (616) , 0.0001
O2 saturation, % 95 (62) 97 (64) 96 (66) 97 (62) NS
6-min-walk distance, m 377.8 (6124) NA NA NA NA
Inhaled steroid usage 4 0 0 0 NS
BAL culture positive, n (%) 5 (7.5) 0 0 0 NS
Definition of abbreviations: BAL = bronchoalveolar lavage; COPD = chronic obstructive pulmonary disease; IPF = idiopathic pulmonary fibrosis; NA = not
available, NS = not significant.
Data are means 6 SD unless otherwise noted.
*P value is comparison between the IPF and combined control group. The table provides the demographics for the subject panels used in the study.
Details are provided for IPF cases, subjects with COPD, healthy subjects, as well as combined control subjects (COPD plus healthy subjects).
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the 16S rRNA gene/ml of BAL, which was
more than twofold higher than the copy
number in control subjects (P , 0.0001).
Within the control subjects, there was no
signiﬁcant difference in bacterial load
between subjects with COPD and healthy
control subjects. The patients with IPF
had a signiﬁcantly higher bacterial burden
than both control subgroups (P = 0.006
and P = 0.0007, respectively) (Figure 1).
Sputum samples from 20 control subjects
taken the day before bronchoscopy
demonstrated a mean bacterial load of
3.1 3 109 copies of the 16S rRNA gene/ml,
32 times higher than the subsequent lavage
(P , 0.0001). There was no correlation
between the bacterial load and either the
total or differential BAL cell counts. The
negative control samples (sterile saline
aspirated through the suction channel
of the bronchoscope) yielded a bacterial
burden close to or below the lower limit
of qPCR quantiﬁcation (1,000 copies/ml).
Although BAL return differed between
IPF cases and control subjects (124.4 ml 6
31 vs. 96 ml 6 41; P , 0.001), there was
no relationship between bacterial burden
and BAL yield (Spearman r = 20.027,
P = 0.78). Importantly, no ciliated epithelial
cells (which may have been indicative
of large airway contamination) were seen
in the BAL returns.
Within the subjects with IPF we
found bacterial burden to be associated
independently with the rs35705950
polymorphism in the promoter of the
mucin gene MUC5B genotype (P = 0.01),
with patients possessing a minor allele
having a lower bacterial burden (see Figure
E1 in the online supplement). There was
no correlation between bacterial burden
and baseline disease severity, measured
by either FVC (Spearman r = 20.11, P =
0.49), total lung capacity (Spearman
r = 20.12, P = 0.49), DLCO (Spearman
r = 20.20, P = 0.21), or the composite
physiologic index (Spearman r = 0.06,
P = 0.70).
To test for a relationship between
bacterial load and disease progression,
we partitioned the patients with IPF into
groups with progressive or stable disease.
As a 6-month decline of greater than 10%
in FVC is associated with an increased
risk of mortality in IPF (30), we deﬁned
disease progression as either a relative
decline in FVC of greater than 10% or
death. Individuals with IPF whose disease
had progressed at 6 months (n = 22)
demonstrated a signiﬁcantly higher BAL
bacterial burden when compared with
subjects with stable disease (2.35 3 108 6
1.68 3 108 compared with 1.41 3 108 6
1.40 3 108) copies of the 16S rRNA gene/
ml of BAL; P = 0.02). To investigate this
relationship further, we separated the
subjects with IPF into tertiles based on
the 16S rRNA gene copy number/ml of
BAL. Individuals in the top tertile with
the highest bacterial burden were at
a substantially increased risk of mortality
compared with subjects in the bottom
tertile (i.e., those with the lowest
bacterial burden) (hazard ratio, 4.59;
95% conﬁdence interval, 1.05–20)
(Figure 2). There were no signiﬁcant
differences in sex, age, smoking status,
or disease severity between the patients
with IPF within these tertiles of bacterial
burden.
Microbial Communities
We then compared the baseline microbiota
of the subjects with IPF and the control
subjects (Figure 3). Sequencing revealed
Streptococcus, representing 30% of total
reads, was the most common genus in
subjects with IPF, followed by Prevotella
(10.9%) and Veillonella (10.6%). In the
combined control subjects, Streptococcus
also formed the most common genus
(27.1% of total reads) followed by Prevotella
(11.6%) and Veillonella (7.1%). We found
no signiﬁcant differences in the BAL
microbiota between the healthy control
subjects and subjects with COPD
(Figure 3). The microbial communities
of subjects with IPF were by contrast less
diverse (Shannon diversity index, 3.816 0.08
vs. 4.11 6 0.10; P = 0.005) and contained
fewer numbers of OTUs (44.89 6 1.50 vs.
54.33 6 1.86 OTUs; P , 0.0001) than the
control subjects. We discovered in patients
compared with control subjects a 3.4-fold
increase in sequence reads of a potentially
pathogenic Haemophilus sp. (OTU 739)
(36.0 6 7.5 vs. 10.5 sequences 6 1.9
sequences; P, 0.001); a 2.1-fold increase in
a Neisseria sp. (OTU 594) (57.9 6 9.4 vs.
27.5 6 5.5 sequences; P , 0.01); a 1.4-fold
increase in a Streptococcus sp. (OTU 881)
(113.6 6 11.4 vs. 82.2 6 8.9 sequences;
P , 0.05); and a 1.5-fold increase in a
Veillonella sp. (OTU 271) (84.8 6 5.7
vs. 56.6 6 4.5 sequences; P , 0.001)
(Figure 4). There were no demonstrable
changes in community structure or
composition between patients with IPF
with progressive or stable disease, despite
the differences in overall bacterial burden.
There were no signiﬁcant differences in the
BAL microbiota between the healthy
control subjects and subjects with COPD,
and exclusion of subjects with COPD from
the control panel did not change the
differences detected. When our data were
analyzed with patients on corticosteroids
excluded from the IPF cohort, the observed
differences in the microbiota remained
unchanged.
Standard microbial culture of BAL
was positive in ﬁve cases of IPF (7.6%)
but none of the control subjects. In each
instance, the cultured bacterial species were
also identiﬁed by the pyrosequencing data,
although they were not always the most
abundant species within the microbiome.
We then examined, using a stepwise
logistic regression, whether bacterial burden
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Figure 1. Bacterial burden in patients with
idiopathic pulmonary fibrosis (IPF) compared
with control subjects. Patients with IPF (red)
(n = 64) had a significantly higher bacterial
burden than subjects with chronic obstructive
pulmonary disease (COPD) (green) (n = 17)
and the healthy control subjects (blue) (n = 27)
(P = 0.006 and P = 0.0007, respectively). The
box signifies the 25th and 75th percentiles,
and the median is represented by a short line
within the box. BAL = bronchoalveolar lavage.
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and the relative abundance of these
OTUs were associated independently with
a diagnosis of IPF. Age and smoking status
were included in the model to control
for possible confounding. Total bacterial
burden and the numbers of three speciﬁc
OTUs (Veillonella sp. [OTU 271], Neisseria
sp. [OTU 594], and Streptococcus sp.
[OTU 881]) all remained signiﬁcantly
associated with a diagnosis of IPF (P =
0.001, 0.007, and 0.01, respectively). The
overall R2 was 0.66 with age in the model
and was 0.51 without age. The abundance
of Haemophilus OTU 739 was strongly
correlated with Neisseria OTU 594
(Spearman r = 0.42). Removal of Neisseria
from the model made Haemophilus
OTU 739 signiﬁcant (P = 0.02; b = 0.038 6
0.016) with minimal change in the overall
multivariate R2 (0.657).
Discussion
In this study we demonstrated that when
compared with control subjects, patients
with IPF have a higher bacterial load in
bronchoalveolar lavage ﬂuid and signiﬁcant
differences in the composition and diversity
of their microbiota. We have also shown that
an increased bacterial load at the time of
diagnosis identiﬁed patients with more rapidly
progressive IPF and a higher risk of mortality.
The baseline bacterial communities we
observed in patients with IPF and control
subjects contained organisms such as
Streptococcus, Prevotella, Fusobacterium,
and Haemophilus, which are commonly
found in the airways of healthy subjects,
subjects with asthma, and patients with
COPD (31–34). We discovered differences
in speciﬁc OTUs between cases and control
subjects, notably the presence of more
abundant Streptococcus, Haemophilus,
Neisseria, and Veillonella spp. in the
patients with IPF. This indicated that total
bacterial load and the abundances of these
speciﬁc OTUs provided independent
predictors of IPF case status and suggested
that potentially pathogenic OTUs may be
acting synergistically within a context of
an increased bacterial load.
The rs35705950 polymorphism in the
promoter of the mucin gene MUC5B
confers an increased risk of developing
IPF (4) but paradoxically confers a survival
beneﬁt among patients with IPF (7). We
found bacterial burden to be associated
independently with rs35705950 genotype
(P = 0.01), with patients possessing a minor
allele having a lower bacterial burden,
suggesting a direct relationship between
host immunity and bacterial load. The
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*
Figure 2. Kaplan–Meier curves for time until death. Subjects with idiopathic pulmonary fibrosis
(IPF) in the tertile with the highest bacterial load (16S copy number/ml of bronchoalveolar lavage) are
shown in red, and were at increased risk of mortality compared with subjects with IPF in the tertile
with the lowest bacterial burden, shown in blue (hazard ratio, 4.59; 95% confidence interval,
1.05–20).
Healthy Controls COPD
Staphylococcus 338
Gemella 803
Lactobacillus 331
Granulicatella 482
Streptococcus 592
Streptococcus 881
Streptococcus 779
Streptococcus 617
Oribacterium 753
Catonella morbi 633
Johnsonella 637
Moryella 306
Eubacterium saburreum 736
Peptostreptococcus 14
Mogibacterium neglectum 143
Eubacterium 488
Eubacterium brachy 494
Parvimonas 777
Fusobacterium 816
Fusobacterium 852
Leptotrichia 719
Leptotrichia 686
Leptotrichia 510
Prevotella 116
Prevotella 478
Prevotella 727
Prevotella nanceiensis 258
Prevotella 207
Prevotella 345
Prevotella 768
Prevotella 509
Prevotella 694
Prevotella 696
Prevotella oris 61
Porphyromonas 103
Porphyromonas gingivalis 762
Tannerella 285
Porphyromonas 376
Capnocytophaga gingivalis 707
Capnocytophaga 663
Capnocytophaga 69
Selenomonas 577
Selenomonas 309
Selenomonas 90
Veillonella 129
Veillonella 271
Veillonellaceae 353
Atopobium 0
Tropheryma whipplei 865
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Pseudomonas aeruginosa 11
Pseudomonas 756
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Escherichia coli 583
Haemophilus 433
Haemophilus 739
Actinobacillus 591
Burkholderia 360
Burkholderia 655
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Oxalobacteraceae 729
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Figure 3. A phylogenetic tree and heatmap of bacterial 16S rRNA sequences grouped by disease status: idiopathic pulmonary fibrosis (IPF), chronic
obstructive pulmonary disease (COPD), and healthy control subjects. This depicts operational taxonomic units (OTUs) with identifiers organized
phylogenetically by tree with abundance indicated by the color (darker blue or red more abundant). The OTUs of interest are highlighted in red.
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more densely populated and less diverse
bacterial communities of the lower airways
in IPF may provide persistent stimuli for
repetitive alveolar injury. The temporal
and spatial heterogeneity observed in usual
interstitial pneumonia (the histological
lesion of IPF) speaks to the likely
importance of repetitive injury as a major
factor in the pathogenesis of the disease
(35). The bacterial communities of the
lower airways are a plausible candidate for
this trigger, and regional differences in
the bacterial microbiome (36) may help
explain the distribution of the ﬁbrotic
lesions in IPF.
We do not ﬁnd any association between
speciﬁc microbes and disease progression.
Han and colleagues have recently presented
data for the microbiota of individuals
with IPF in a retrospective study (37). They
demonstrate the most commonly identiﬁed
bacteria in the lungs of individuals with
IPF were Prevotella sp., Veillonella sp.,
and Escherichia sp., the presence of which
we conﬁrmed in our cohort. The authors
found that the presence of a speciﬁc
Streptococcus sp. or Staphylococcus sp.
above a statistically modeled threshold was
associated with a composite endpoint for
disease progression. However, less than
half of their patients had either of these
bacteria in levels above the threshold,
suggesting neither can fully explain
disease pathogenesis or progression (38).
We are able to conﬁrm the presence of
Streptococcus sp. or Staphylococcus sp. in
the IPF microbiome, and a longer follow-up
period has allowed us to investigate for
associations between the microbiome and
survival. We demonstrate that although
there are clear differences in the IPF
microbiome compared with healthy
individuals, it is the bacterial load that
effects survival.
We cannot not draw any conclusions
regarding the causal nature or not of this
altered respiratory microbiome in IPF.
Trials of antibiotic therapy may help
elucidate this. There has recently been
a large placebo-controlled multicenter study
evaluating the use of Septrin in the broader
category of ﬁbrotic idiopathic interstitial
pneumonias. This treatment was not well
tolerated, and there was ultimately no
detectable difference in the primary
endpoint. Despite this, in subjects who
tolerated Septrin therapy there was
a reduction in infections and subsequent
mortality. The authors hypothesize that
this observation may be a result of Septrin’s
antimicrobial effects, but it is difﬁcult to
draw conclusions because of its concurrent
antiinﬂammatory actions. However,
combined with our data here and the
high mortality associated with bacterial
respiratory tract infections in IPF, this
observation does suggests a more targeted
and well-tolerated antibiotic should be
trialed in an IPF cohort.
There is a wide variation in the reported
qPCR values for bacterial load in BAL,
and the absolute quantiﬁcation is dependent
on multiple factors from sampling to
processing, hindering comparisons between
studies with differing primers and qPCR
conditions. The bacterial loads reported
here are comparable with other studies
(36, 39), and our conclusions are based
on relative values between cases and
control subjects and those with stable or
progressive disease. The inclusion of
negative sampling control subjects (sterile
saline aspirated through the suction
channel of the bronchoscope), which
yielded bacterial burden close to or below
the lower limit of qPCR quantiﬁcation,
also demonstrates that the qPCR results
are not simply artifact from a sampling or
processing error.
Our study has a number of limitations.
IPF is a disease of the lung parenchyma,
whereas we used BAL ﬂuid to sample the
distal airways. Direct sequencing of lung
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Figure 4. Differences in bacterial operational taxonomic unit (OTU) frequencies between idiopathic pulmonary fibrosis (IPF) and control subjects. Box
plots showing significant differences (P , 0.01) in OTUs between control subjects (blue) and patients with IPF (red). Triangles represent subjects with
chronic obstructive pulmonary disease (COPD), circles healthy control subjects, and squares subjects with IPF. The box signifies the 25th and
75th percentiles, and the median is represented by a short line within the box.
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tissue may provide further information on
the pulmonary microbiome (40), but lung
biopsies are undertaken infrequently in
IPF, and gathering true healthy control
samples would be extremely difﬁcult. We
used the oropharyngeal route to pass
a bronchoscope into the lungs, and
some secretions from the upper airways
will have been carried on the tip of the
bronchoscope. Any carryover, however,
will have been heavily diluted by the 240 ml
of BAL ﬂuid. The high percentage of
BAL return and an absence of ciliated
epithelial cells in BAL ﬂuid (indicative of
large airway contamination) provided
conﬁdence that our BAL return was
primarily derived from the distal airspace.
We note that strong similarities have been
seen between microbiota identiﬁed from
BAL ﬂuid and from surgically removed
lung tissue in which upper airway
contamination was not an issue (36).
Most importantly, we used the same
protocols and procedures for cases
and control subjects, so any contamination
will not have systematically inﬂuenced
our results. Although there is currently
no universally adopted approach to
minimize potential upper airways
carryover, the use of protected BAL
ﬂuid, pro-BAL catheters, or protected
catheter brushes could help avoid
contamination.
Although the combination of 16S
rRNA PCR with next-generation
sequencing allows the parallel sequencing
of large number of samples at relatively
low cost and without the need for culture,
there are limitations to the technique.
The most signiﬁcant are the biases
introduced by primer design, which may
select for, or against, particular bacteria (41).
A further limitation to our study is that
we did not assess for the presence or
absence of other potential nonbacterial lung
pathogens. Although a substantial study
found no evidence of detectable viruses by
PCR of BAL ﬂuid from 40 stable patients
with IPF (13), it is conceivable that some
differences in progression could be due to
the presence of respiratory viruses in our
sample.
IPF is a fatal progressive disease with
a median survival of 2 to 3 years. There
are no effective treatments for the illness.
We have demonstrated that increased
bacterial load at the time of diagnosis
identiﬁes patients with more rapidly
progressive IPF and a higher risk of
mortality. It is not possible to conclude
from our results whether the presence of
an altered microbiome is the cause or
a result of the destruction of the normal
lung architecture. Although requiring
further validation in larger prospective
cohorts, our ﬁndings nevertheless
provide a strong rationale for trials
of antimicrobial therapy in IPF.
Such trials will help determine the
etiological role of bacteria in the
progression of IPF while at the same
time investigating a novel potential
treatment for a currently intractable
and fatal disease. n
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